Key facts
- This page summarizes Jonathan Berlent's Form 4 filing for Cure Pharmaceutical Holding Corp. (AVRW).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2021, 16:05.
Jonathan Berlent - 27 May 2021 Form 4 Insider Report for Cure Pharmaceutical Holding Corp. (AVRW)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- AVRW
- Reported as of
- 27 May 2021
- Net transaction value
- +$6,900
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2021, 16:05:35 UTC
- Prior SEC filing
- 27 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Berlent
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Berlent filed Form 4 for Cure Pharmaceutical Holding Corp. (AVRW) on 01 Jun 2021.
Change
- Previous filing in this sequence was filed on 27 May 2021.
- Current net transaction value: +$6,900.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVRW
transaction
Common Stock
Purchase
- Transaction value
- $6,900
- Shares
- +10,000
- Change %
- Price
- $0.6900
- Shares after
- 10,000
- Date
- 27 May 2021
- Ownership
- Direct
* marks a reported price that did not pass the local price check.